UC
RETA

Unterberg Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Unterberg Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$1.64M Sell
20,000
-5,000
-20% -$352K 2.11% 17
2018
Q2 		$874K Hold
25,000
– – 1.04% 21
2018
Q1 		$513K Hold
25,000
– – 0.6% 28
2017
Q4 		$708K Buy
+25,000
New +$698K 0.87% 26

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Unterberg Capital's RETA Position: Q3 2018 in Review

Unterberg Capital reduced its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 20% in Q3 2018, selling an estimated $352K and leaving 20,000 shares worth $1.64M. The position accounts for 2.11% of the portfolio, ranked #17.

Unterberg Capital first reported a position in RETA in Q4 2017 and has held it in 4 quarters since. 119 funds tracked by Wall St. Rank hold RETA as of Q3 2018.

  • Unterberg Capital held 20,000 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $1.64M as of Q3 2018.
  • Unterberg Capital sold 5,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2018, an estimated $352K.
  • Reata Pharmaceuticals, Inc. Class A Common Stock made up 2.11% of Unterberg Capital's portfolio in Q3 2018, its #17 holding.
  • Unterberg Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and has held it in 4 quarters since.
  • 119 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2018.

Based on Unterberg Capital's 13F filing for Q3 2018, filed 24 Oct 2018.